Global phosphoproteomics analysis of HPB and GI tumours
Research type
Research Study
Full title
Personalising treatment with global phosphoproteomics analysis in patients with hepato-pancreato-biliary (HPB) and gastrointestinal tumours
IRAS ID
137380
Contact name
Alberto Quaglia
Contact email
Sponsor organisation
King's College Hospital NHS Foundation Trust
Clinicaltrials.gov Identifier
N/A, N/A
Research summary
A significant proportion of patients diagnosed with hepato-pancreato-biliary (HPB) and gastrointestinal (GI) tumours present at an advanced stage when therapeutic options are limited. Current treatment regimens in these diseases do not personalize therapy based on detailed knowledge of the cancer pathways in each patient. An understanding of the cancer pathways in each patient can help tailor drug treatment to maximise response and minimise side effects. In this study we will investigate the cancer pathways in individual patients to provide the clinician with important personalised data about likely response and side effects with different drug regimens.
Protein phosphorylation is a common process that alters the activity of hundreds of proteins that play a critical role in cancer pathways. In many cases, phosphorylation results in switch-like changes in protein function that affects cell growth, type and death. Abnormalities in these proteins pathways can contribute to cancer development.
Key proteins and cancer pathways can now be identified at a more comprehensive level using a protein mass spectrometry workflow that offers superior coverage and throughput. The workflow has been developed to identify and quantify thousands of proteins and their phosphorylation sites. In this study, we plan to apply this workflow to analyse HPB and GI tissue specimens to determine key proteins and cancer pathways that may help tailor drug treatment for individual patients.
The study will run for seven years and be conducted at King’s College Hospital NHS Foundation Trust. The initial phase will analyse tissue to determine key proteins and cancer pathways. Later phases will correlate tissue and blood analysis with clinical outcomes to determine usefulness.
REC name
London - Chelsea Research Ethics Committee
REC reference
14/LO/1560
Date of REC Opinion
11 Sep 2014
REC opinion
Further Information Favourable Opinion